<?php /** * The template for displaying the header * * This is the template that displays all of the <head> section, opens the <body> tag and adds the site's header. * * @package HelloElementor */ if ( ! defined( 'ABSPATH' ) ) { exit; // Exit if accessed directly. } $viewport_content = apply_filters( 'hello_elementor_viewport_content', 'width=device-width, initial-scale=1' ); $enable_skip_link = apply_filters( 'hello_elementor_enable_skip_link', true ); $skip_link_url = apply_filters( 'hello_elementor_skip_link_url', '#content' ); ?> <!doctype html> <html <?php language_attributes(); ?>> <head> <meta charset="<?php bloginfo( 'charset' ); ?>"> <meta name="viewport" content="<?php echo esc_attr( $viewport_content ); ?>"> <link rel="profile" href="https://gmpg.org/xfn/11"> <?php wp_head(); ?> </head> <body <?php body_class(); ?>> <?php wp_body_open(); ?> <?php if ( $enable_skip_link ) { ?> <a class="skip-link screen-reader-text" href="<?php echo esc_url( $skip_link_url ); ?>"><?php echo esc_html__( 'Skip to content', 'hello-elementor' ); ?></a> <?php } ?> <?php if ( ! function_exists( 'elementor_theme_do_location' ) || ! elementor_theme_do_location( 'header' ) ) { if ( hello_elementor_display_header_footer() ) { if ( did_action( 'elementor/loaded' ) && hello_header_footer_experiment_active() ) { get_template_part( 'template-parts/dynamic-header' ); } else { get_template_part( 'template-parts/header' ); } } }

Best Promising COVID-19 Drugs in 2023

Table of Contents

Always consult a healthcare professional for the most up-to-date information on COVID-19 treatments. Some of the most promising Covid-19 drugs at the time include:

  1. Remdesivir (Veklury): Remdesivir is an antiviral drug that was initially developed to treat Ebola. It has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA) for the treatment of hospitalized COVID-19 patients. Remdesivir has been shown to shorten the recovery time in some patients.
  2. Dexamethasone: Dexamethasone is a corticosteroid that has been found to reduce the risk of death in severely ill COVID-19 patients requiring oxygen or mechanical ventilation. The drug works by reducing inflammation and modulating the immune system’s response.
  3. Monoclonal antibodies: Monoclonal antibodies such as bamlanivimab, etesevimab, casirivimab, and imdevimab have been authorized for emergency use to treat mild to moderate COVID-19 cases in high-risk patients. These laboratory-made antibodies mimic the immune system’s ability to fight off viruses, targeting specific viral proteins and preventing the virus from infecting cells.
  4. Baricitinib (Olumiant): Baricitinib, a Janus kinase (JAK) inhibitor, is an anti-inflammatory drug initially developed to treat rheumatoid arthritis. In combination with remdesivir, it has been authorized for emergency use to treat hospitalized COVID-19 patients requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
  5. Tocilizumab (Actemra) and Sarilumab (Kevzara): These drugs are interleukin-6 (IL-6) receptor antagonists, which work by blocking the action of IL-6, a protein involved in the immune response. They have been used to treat severe cases of COVID-19, particularly in patients experiencing a cytokine storm, a severe immune overreaction that can lead to organ damage and failure.

Please note that the information provided here may change as new data and research become available. Consult a healthcare professional for the most current information on COVID-19 treatments.

More resources

Newsletter

Sign up our newsletter to get update, insight and information